On November 20, GeneDx Holdings fell 5.28% in Regular Trading, trading at $46.67 per share, with turnover of $4.91 million.
The clearest recent catalyst is the company’s leadership transition announcement alongside a reaffirmation of full-year guidance, with the market continuing to assess execution risks during the CEO handoff.
GeneDx said Everett Cunningham will become CEO and a board member on or before December 15, while Katherine Stueland will step down and remain an adviser through January 31. The company also reiterated full-year revenue guidance of $475 million to $490 million. Supporting operating context was mixed: third-quarter adjusted EPS of $0.28 and revenue of $123.1 million both exceeded expectations, but fourth-quarter revenue guidance of $135 million trailed the $142.6 million consensus, which helps explain why sentiment remains cautious despite the guidance reaffirmation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments